| Little et al.25 (2005) | | | | All implants associated with improvement in terms of pain and range of motion, without any significant differences between implant types | |
| Implant 1 | 33 | 61 | Souter-Strathclyde | | 85% 5-year survival |
| Implant 2 | 33 | 67 | Kudo | | 93% 5-year survival |
| Implant 3 | 33 | 68 | Coonrad-Morrey | | 90% 5-year survival |
| Ewald et al.29 (1993) | 312 | 69 | Capitellocondylar | 91/65; increased range of motion 27° | 22 complications (loosening [3], infection [6], dislocation [5], reoperation [8]) |
| Weiland et al.30 (1989) | 45 | 86 | Capitellocondylar | 88/58; increased range of motion 16° | 4 complications (infection [2], dislocation [2]) |
| Rosenberg and Turner31 (1984) | 28 | 35 | Capitellocondylar | 89/60; increased range of motion 13° | 9 complications (loosening [2], infection [2], dislocation [4], reoperation [1]) |
| Davis et al.32 (1982) | 30 | 40 | Capitellocondylar | 85/77; increased range of motion 25° | 7 complications (infection [2], dislocation [4], release ulnar nerve [1]) |
| Schemitsch et al.33 (1996) | 46 | 48 | Capitellocondylar | 90/69; increased range of motion 27° | 7 complications (loosening [3], dislocation [3], release ulnar nerve [1]) |
| Geschwend et al.34 (1999) | 65 | 162 | GSB III | 92% doing well at the time of follow-up; increased range of motion 37° | 18 complications (loosening [3], infection [1], dislocation [10], reoperation [4]) |
| Machner et al.35 (1999) | 34 | 44 | GSB III | 85/43; increased range of motion 39° | 4 complications (infection [3], release ulnar nerve [1]) |
| Tanaka et al.36 (2001) | 50 | 156 | Kudo | 77/34; increased range of motion 24° | 4 complications (loosening [4]) |
| Verstreken et al.37 (1998) | 16 | 35 | Kudo | 89/57; increased range of motion 27° | 5 complications (loosening [2], dislocation [2], release ulnar nerve [1]) |
| Kudo and Iwano38 (1990) | 43 | 46 | Kudo | 80/37; increased range of motion 25° | 3 complications (dislocation [1], reoperation [2]) |
| Rahme39 (2002) | 30 | 60 | Kudo | 91/39; increased range of motion 17° | 6 complications (loosening [2], infection [1], dislocation [1], fracture [1], reoperation [1]) |
| Soni and Cavendish40 (1984) | 80 | 42 | Liverpool | 81% doing well at the time of follow-up; increased range of motion 32° | 22 complications (loosening [8], infection [4], release ulnar nerve [2], reoperation [8]) |
| Dhar and Beddow41 (1994) | 9 (using original humeral component) | 141 | Liverpool | 76/63; increased range of motion 13° | 5 complications (loosening [5]) |
| 11 (using modified humeral component) | 69 | Liverpool | 82/67; increased range of motion 27° | |
| Risung42 (1997) | 118 | 51 | Norway | 89/68; increased range of motion 21° | 15 complications (loosening [1], infection [3], dislocation [2], release ulnar nerve [2], fracture [1], reoperation [6]) |
| Yanni et al.43 (2000) | 59 | 78 | Roper-Tuke | 88/56; increased range of motion 29° | 5 complications (infection [2], reoperation [3]) |
| Allieu et al.44 (1998) | 20 | 114 | Roper-Tuke | 80/41; increased range of motion 31° | 5 complications (loosening [3], infection [2]) |
| Lyall et al.45 (1994) | 19 | 41 | Souter-Strathclyde | 89.5%; increased range of motion 36° | 3 complications (loosening [1], fracture [1], reoperation [1]) |
| Van der Lugt et al.46 (2004) | 204 | 77 | Souter-Strathclyde | 85.4%; increased range of motion 25° | 41 complications (loosening [16], infection [10], dislocation [4], release ulnar nerve [3], fracture [7], reoperation [1]) |
| Burnett and Fyfe47 (1991) | 23 | 36 | Souter-Strathclyde | 77.2%; increased range of motion 24° | 6 complications (loosening [2], dislocation [2], fracture [1], reoperation [1]) |
| Sjödén et al.48 (1995) | 19 | 60 | Souter-Strathclyde | 89.5%; increased range of motion 12° | 6 complications (loosening [5], dislocation [1]) |
| Dainton and Hutchins49 (2002) | 44 | 72 | Souter-Strathclyde | 88%; increased range of motion 18° | 12 complications (loosening [8], infection [1], release ulnar nerve [1], fracture [2]) |